| Izvleček: | BACKGROUND: Lobeline is a partial nicotine agonist, which has been used in a variety of commercially available preparations to help stop smoking. OBJECTIVES: The objective of this review was to assess the effects of lobeline on long term smoking cessation. SEARCH STRATEGY: We searched the Cochrane Tobacco Addiction Group trials register. SELECTION CRITERIA: Randomized trials comparing lobeline to placebo or an alternative therapeutic control, which reported smoking cessation with at least six months follow-up. DATA COLLECTION AND ANALYSIS: We extracted data in duplicate on the type of subjects, the dose and form of lobeline, the outcome measures, method of randomisation, and completeness of follow-up. MAIN RESULTS: We identified no trials meeting the full inclusion criteria including long term follow-up. REVIEWER'S CONCLUSIONS: There is no evidence available from long term trials that lobeline can aid smoking cessation.
|
|---|